Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21668752 | 0.90 | OPRK1 (0.38) | ACACBMAPTOPRK1LIPGALDH1A1 | |
| SCHEMBL21638214 | 0.88 | LIPG (0.41) | ACACBLIPGLIPCKDM1A | |
| SCHEMBL21638215 | 0.88 | LIPG (0.41) | ACACBLIPGLIPCKDM1A | |
| SCHEMBL23965786 | 0.86 | PRKD3 (0.43) | ACACBMAPTALDH1A1LMNAKDM4E | |
| SCHEMBL21638303 | 0.85 | ALDH1A1 (0.44) | MAPTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL21638231 | 0.78 | PRKAB2 (0.40) | ACACBLIPGLIPC | |
| SCHEMBL21638230 | 0.78 | PRKAB2 (0.40) | ACACBLIPGLIPC | |
| SCHEMBL23965738 | 0.78 | MAPT (0.53) | ACACBMAPTALDH1A1LMNAKDM4E | |
| SCHEMBL21668775 | 0.78 | MAPT (0.53) | ACACBMAPTALDH1A1LMNAKDM4E | |
| SCHEMBL23965802 | 0.77 | LIPG (0.40) | ACACBMAPTLIPGLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161830-B2 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | FUJIFILM CORPORATION (JP) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161830-B2 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | HAVCR2, HBS1L, PHKB | ACACB 3638/4885MAPT 2580/4885OPRK1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.